undamentalytics Newsletter
Sign in

Nutriband Inc. revenue

Nutriband Inc.'s revenue was $2.0m in fiscal 2026, down 4.8% on the year before. Since fiscal 2019 ($245,285) it has grown at a compound 35.3% a year. Over the last twelve months it was $1.6m.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2019Jan 20192020Jan 20202021Jan 20212022Jan 20222023Jan 20232024Jan 20242025Jan 20252026Jan 2026LTMJul 2026
Revenue2451199441,4222,0802,0852,1402,0371,618
Growth on the year before—−51.3%+690.6%+50.7%+46.2%+0.3%+2.6%−4.8%—
Gross profit−43−430316554750862743566536
Gross margin−17.5%—33.5%39.0%36.1%41.3%34.7%27.8%33.1%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to January 31, 2026
Geography
Region Revenue Share YoY
United States $2M 99.6% ▼ 5.2%
Outside the US $7,630 0.4% —

From Nutriband Inc.'s 10-K filed April 29, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Pharmaceuticals: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Nutriband Inc. $1.6m -37.3% -10.8%
Lipocine Inc. $1.6m -62.7% 205.6%
China SXT Pharmaceuticals, Inc. $1.1m -34.6% —
60 Degrees Pharmaceuticals, Inc. $1.1m 73.2% 74.9%
Eyepoint, Inc. $2.8m -94.6% -57.9%
Scienture Holdings, Inc. $821,315 540.6% -58.5%

Compare with peers

Head to head: LPCN vs NTRBNTRB vs SXTCNTRB vs SXTPEYPT vs NTRB

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Nutriband Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Nutriband Inc.